gw9662 and shogaol

gw9662 has been researched along with shogaol* in 1 studies

Other Studies

1 other study(ies) available for gw9662 and shogaol

ArticleYear
6-Shogaol attenuates LPS-induced inflammation in BV2 microglia cells by activating PPAR-γ.
    Oncotarget, 2017, Jun-27, Volume: 8, Issue:26

    6-Shogaol, a pungent agent isolated from Zingiber officinale Roscoe, has been known to have anti-tumor and anti-inflammatory effects. However, the anti-inflammatory effects and biological mechanism of 6-Shogaol in LPS-activated BV2 microglia remains largely unknown. In this study, we evaluated the anti-inflammatory effects of 6-Shogaol in LPS-activated BV2 microglia. 6-Shogaol was administrated 1 h before LPS treatment. The production of inflammatory mediators were detected by ELISA. The expression of NF-κB and PPAR-γ were detected by western blot analysis. Our results revealed that 6-Shogaol inhibited LPS-induced TNF-α, IL-1β, IL-6, and PGE2 production in a concentration dependent manner. Furthermore, 6-Shogaol inhibited LPS-induced NF-κB activation by inhibiting phosphorylation and nuclear translocation of NF-κB p65. In addition, 6-Shogaol could increase the expression of PPAR-γ. Moreover, inhibition of PPAR-γ by GW9662 could prevent the inhibition of 6-Shogaol on LPS-induced inflammatory mediator production. In conclusion, 6-Shogaol inhibits LPS-induced inflammation by activating PPAR-γ.

    Topics: Anilides; Animals; Catechols; Cell Line; Cell Survival; Cytokines; Inflammation; Inflammation Mediators; Lipopolysaccharides; Mice; Microglia; NF-kappa B; PPAR gamma

2017
chemdatabank.com